{‘She has little experience’: this American scientific field braces for Høeg's appointment at the FDA.

Given that the US undertakes sweeping changes to its immunization recommendations, an unexpected name appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid vaccinations throughout the pandemic and has zeroed in on potential fatalities following Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Schedule

Agency leaders had intended to reveal sweeping changes to the pediatric vaccination calendar earlier this month, bringing the US with the Danish immunization schedule, it is understood – a substantial departure that would put the US at odds with much of the world with little proof for benefit. This reveal has been delayed until the next year.

In place of the top vaccines chief, Dr. Høeg is listed to address the audience at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to head the office this calendar year.

A New Direction at the FDA

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine centers as Høeg and Prasad strengthen their influence at the FDA – and it points to a renewed priority upon dismantling already-approved vaccines at the FDA.

The new acting director has repeatedly called for halting certain childhood vaccine recommendations in the US to become more like Denmark, a country with universal health coverage and a number of inhabitants about the size of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccines – usually the domain of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Background

Dr. Høeg has little discernible track record in drug development, approval processes or administrative roles, which has been customary for previous heads of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have any of the qualifications” for leading the CDER, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in leading a large organization. She is not an expert in drug approvals.”

Previous directors of CBER would “understand laws and regulations and the research of medication creation”, noted Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that former directors who headed CBER have had.”

This division has an enormous workload at the agency, she stated.

“Everybody just pays attention on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There’s a biosimilars division, over-the-counter program and other areas, and every single one need to be looked after,” Woodcock explained. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial administrative aspect to the role, which supervises more than 5,000 employees. “It is a huge management job, if you perform it correctly,” the former official concluded.

Agency Reaction and Controversial Policies

Regarding inquiries about Høeg’s credentials and whether this selection represents increased cooperation among FDA leaders on vaccines, a spokesperson stated that the “concerns rely on inaccurate presumptions”.

“Her experience is consistent with the duties of her role,” the representative explained, citing the period Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg takes over the commissioner’s controversial fast-track approval initiative, a contentious expedited drug-approval program that apparently worried her former heads. “How are these medications being picked for this fast-track system? Who takes the choices?” Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards less stringent regulations of pharmaceuticals, except for immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if concerning, history, critics have noted. She released a study using non-validated volunteer-provided data to assess the rate of myocarditis following COVID-19 vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the current government encompassed altering rules for novel immunizations and discontinuing “non-essential” immunizations, she stated after the election on a audio program. At the agency, Høeg has reportedly floated the idea of excluding adolescent males from receiving Covid vaccinations.

“She’s an all-around ideologue who begins with her conclusions and tailors the evidence to retrofit the data in a extremely disingenuous, untruthful manner,” Howard stated.

Taking Control and a “Revenge Tour”

Høeg joined fellow contrarians, {like|